LIFE SCIENCE TOOLS MARKET ANALYSIS

Market Size and Trends

The life science tools market is estimated to be valued at USD 136.17 Bn in 2024 and is expected to reach USD 319.35 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 13% from 2024 to 2031.

To learn more about this report, request a free sample copy

The life science tools market is expected to witness positive growth over the forecast period. Key factors, such as increasing R&D spending on drug development, rise in need for cost containment in drug discovery, growth of molecular diagnostics, and technological advancements, are expected to drive the demand for life science tools. Growing focus on precision medicine and companion diagnostics is further expected to propel the market growth. Additionally, factors, such as increasing pharmaceutical outsourcing and rising life expectancy, are anticipated to present lucrative growth opportunities for market players in the coming years.

Increasing Adoption of Organic Growth Strategies Such as Product Launches

Increasing adoption of organic growth strategies such as product launches by the key market players is expected to drive the global life science tools market growth over the forecast period. For instance, in September 2022, F. Hoffmann-La Roche Ltd., a pharmaceutical company, launched the Digital LightCycler System (DLS), a digital polymerase chain reaction (PCR) system that is designed to aid in diagnostics for cancer, genetic disease, and infection. It detects the disease accurately and evaluates trace amounts of specific DNA and RNA targets that are not typically detectable by conventional PCR methods.

Market Concentration and Competitive Landscape

To learn more about this report, request a free sample copy

Nanotechnology is increasingly revolutionizing the life sciences field in pathbreaking ways. The ability to manipulate and study matter at the nanometer level is opening new vistas for advanced research in areas like genomics, proteomics, and molecular biology. Life science tools that work at nanoscale levels are allowing scientists and researchers to gain deeper insights into complex biological processes and systems down to the level of single molecules and cells. Several life science tool companies are leveraging nanotechnology to develop highly innovative and sophisticated lab equipment, instruments, and devices. One prominent area is nanoscale biosensors that can detect and analyze biomolecules with unprecedented sensitivity. Researchers are also seeing the benefits of nanotechnology-enabled high-throughput screening systems for applications like drug discovery. Atomic force microscopes and nanoscale microscopy tools are generating never-before fine-scale images of living tissues and enabling exploration of cellular functions at molecular resolution.

To learn more about this report, request a free sample copy

The high cost of life science tools is one of the major factors restraining the growth of the global life science tools market over the forecast period. The tools and equipment used in life sciences research and development, such as DNA sequencers, incubators, centrifuges, PCR equipment, mass spectrometer, and others, are highly complex and advanced in nature. For instance, in August 2022, according to the data published by Excedr, a provider of scientific equipment leasing and comprehensive service coverage plans intended to assist laboratories and scientists, mass spectrometers instruments can range in price from under USD 10,000 for more basic models to nearly USD 100,000 for advanced and specialized units.

Market Opportunities – Rise of Chronic Diseases

The growing global population and rise of chronic diseases is driving the demand for new diagnostic tools and therapies. This presents opportunities for life science tool companies who can help enable new discoveries. Companies developing tools focused on precision medicine and personalized healthcare will be positioned for growth. There is also a need for multi-omics tools that combine different types of data, from genomics to proteomics.

To learn more about this report, request a free sample copy

The product segment includes consumables, instruments, and services. The consumables segment is estimated to hold 47.7% share of the market in 2024 owing to their indispensable role and adaptable nature across various stages of research and development. Being consumable in nature, these tools require regular replenishment which ensures recurrent sales. Their wide applicability across diverse life science procedures such as sample preparation, nucleic acid purification, cell culture and imaging simplify experimental workflows. Thus, increasing new product launches by key market players are expected to drive the segment growth over the forecast period. For instance, in May, 2022, Thermo Fisher Scientific Inc., a global supplier of scientific instrumentation, announced the launch of a new collection of qPCR biopharma products to accelerate drug development and meet the growing demand for novel biologics. The comprehensive QualTrak suite of qPCR tools consist of a world-class selection of proven applied biosystems solutions including QuantStudio 6 and 7 Pro real-time PCR systems and TaqMan and TaqPath master mixes and assays to empower the biopharmaceutical industry.

Insights, By Technology: Cellular Insights Accelerate Cell Biology Growth

The technology segment includes genomics, proteomics, cell biology, stem cell research, and immunology. The cell biology sub-segment is expected to hold 43.5% of the market share in 2024. Cell biology dominates due to its ability to provide comprehensive cellular insights. Understanding physiological and pathological processes at the cellular level is pivotal for deciphering biological mechanisms and disease pathways. Cell biology tools facilitate interrogation of individual cells, their organization into tissues and complex multicellular structures. Additionally, advances in microscopy, fluidics, mass cytometry, and other technologies have augmented traditional bulk cell analysis. Multi-parametric imaging now illuminates cellular structures, interactions and dynamics in exquisite detail in both 2D and 3D. Such insights are indispensable for phenotypic drug discovery, biomarker evaluation and more. As cellular complexity comes to the fore, understanding how aberrant states manifest at the single-cell level is poised to transform medicine. Cell biology tools facilitate mining health and disease from a systems perspective. Their ability to unravel heterogenous responses and discern rare cellular subpopulations will be immensely valuable for personalized therapeutic strategies.

Insights, By Application: Drug Discovery Innovation Boosts Pharmaceutical Demand

The application segment includes drug discovery and development, clinical diagnostics, genomic and proteomic research, cell biology research, and others. The drug discovery and development sub-segment is expected to hold 31.8% of the market share in 2024 which is driven by associated R&D investments. Life science tools play an indispensable role throughout the drug pipeline from target identification and validation to lead optimization, preclinical, and clinical development. Innovations in screening approaches allow evaluating thousands to millions of compounds against molecular targets simultaneously. This has augmented hit rates and reduced costs of early discovery. Technologies like RNA interference, CRISPR, and organ-on-chip now enable modeling disease mechanisms with greater fidelity. Such advanced models will translate basic research insights into novel targets and pathways more efficiently. Furthermore, as drug development timelines compress, life science tools empower accelerated pharmacokinetic, pharmacodynamics, and toxicological profiling. They assist identifying development candidates rapidly based on human-relevant data versus traditional animal models. Such human-centered approaches boost program success rates and commercial viability.

Regional Insights

To learn more about this report, request a free sample copy

North America remains the dominant region in the global life science tools market and is anticipated to hold 43.5% of the market share in 2024. The presence of major players and strong research infrastructure has propelled the market growth over the years. The region is a hub for the biotechnology and pharmaceutical industries with strong government funding for research activities. Several top universities in the U.S. are actively engaged in research collaborations with industry players, driving innovation. With large healthcare spends, the demand for advanced tools to accelerate drug discovery and development processes continues to rise in the region. Increasing investments by the market players is expected to foster the market growth over the forecast period. For instance, in June 2022, Illumina, Inc., a biotechnology company, announced its investment in Time Boost Capital, a USD 30 million genomics venture fund that offers start-ups that have completed the Illumina Accelerator Cambridge matching funding in order to make advancements in human health. Illumina, Inc. joined a select group of the U.S. and European investors in the life sciences fund, including cornerstone investor LifeArc.

Asia Pacific has emerged as the fastest growing regional market, led by countries such as China and India. Massive government investments to strengthen research capabilities and develop the local manufacturing sector have boosted the adoption of tools across various application areas. The rising spends on healthcare by these nations along with increasing disease prevalence rates is propelling market expansion. Prominent global players have set up manufacturing bases in the region to cater to the growing demand as well as benefit from lower production costs. This has made high-end tools more affordable and assessable for domestic customers. Meanwhile, export opportunities for Asian products continue to rise as the quality standards match international benchmarks. The pool of well-educated and English-speaking talent base further reinforces the growth trajectory of the market.

Market Report Scope

Key Developments

• In August 2023, Bio-Techne, a global life sciences company that provides innovative tools and bioactive reagents for the research and clinical diagnostic communities, collaborated with Akoya Biosciences, a biotechnology company, to co-develop an automated RNAscope workflow for use with the PhenoCycler-Fusion System.
• In February 2023, BD (Becton, Dickinson and Company), one of the leading global medical technology companies, announced the launch of BD Rhapsody HT Xpress System, a new instrument for single-cell multiomics analysis. The system ensures no sample loss and gives scientists the flexibility to analyze multiple samples and different cell sizes and types, such as stem cells or cancer cells, at the same time, to obtain more insights in less time.
• In January 2023, Illumina, Inc., announced that it has entered into a definitive co-development agreement with SomaLogic, a protein biomarker discovery and clinical diagnostics company, to bring the SomaScan Proteomics Assay onto Illumina, Inc. current and future high throughput Next-generation Sequencing (NGS) platforms.
• In January 2023, Takara Bio, a pharmaceutical company, announced a collaboration with BioExcel Diagnostics, a laboratory specialized in molecular diagnostics and clinical genomics, to develop and validate a new high-throughput and comprehensive method for detecting syndromic-based infectious diseases. The method employs real-time polymerase chain reaction (PCR) automation technology and reagents from Takara Bio to detect viruses, bacteria, fungi, and antimicrobial resistance genes specific to the contributing pathogen.
• In September 2022, Hoffmann-La Roche Ltd. launched the Digital LightCycler System (DLS), a digital polymerase chain reaction (PCR) system that is designed to aid in diagnostics for cancer, genetic disease, and infection. It detects the disease accurately and evaluates trace amounts of specific DNA and RNA targets that are not typically detectable by conventional PCR methods.

*Definition: The life sciences tools industry encompasses a wide range of equipment and technologies crucial for research and development in various scientific disciplines like biology, chemistry, and medicine. These tools include instruments, reagents, and consumables used in genomics, proteomics, and metabolomics to analyze genes, proteins, and other molecules for drug discovery, diagnostic tests, and therapies.

Market Segmentation

•  Product Insights (Revenue, USD Bn, 2019 - 2031)
  • Consumables
  • Instruments
  • Services
•  Technology Insights (Revenue, USD Bn, 2019 - 2031)
  • Genomics
  • Proteomics
  • Cell Biology
  • Stem Cell Research
  • Immunology
•  Application Insights (Revenue, USD Bn, 2019 - 2031)
  • Drug Discovery and Development
  • Clinical Diagnostics
  • Genomic and Proteomic Research
  • Cell Biology Research
  • Others
•  End User Insights (Revenue, USD Bn, 2019 - 2031)
  • Academic and Research Institutions
  • Biotechnology and Pharmaceutical Companies
  • Hospitals and Diagnostic Laboratories
  • Contract Research Organizations (CROs)
  • Government and Regulatory Agencies
• Regional Insights (Revenue, USD Bn, 2019 - 2031)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Agilent Technologies, Inc.
  • BD
  • F. Hoffmann-La Roche Ltd
  • Bruker
  • Danaher
  • GE Healthcare
  • Hitachi, Ltd.
  • Illumina, Inc.
  • Merck KGaA
  • Oxford Instruments
  • QIAGEN
  • Shimadzu Corporation
  • Thermo Fisher Scientific Inc. 
  • ZEISS Group
  • Bio-Rad Laboratories
  • Hamilton Company